Mark Massaro, an analyst from BTIG, reiterated the Buy rating on MaxCyte (MXCT – Research Report). The associated price target is $6.00.
Mark Massaro has given his Buy rating due to a combination of factors that highlight MaxCyte’s potential for growth and strategic positioning. Despite a year-over-year decline in total revenue for 2024, MaxCyte demonstrated strong core revenue growth driven by a significant increase in consumable sales. The company also achieved a record number of strategic platform license (SPL) agreements, which are poised to contribute to future economic benefits.
Furthermore, MaxCyte’s acquisition of SeQure Dx is expected to bolster its revenue growth in 2025, even though the guidance provided was more conservative than anticipated. The company’s robust cash position, with no debt, allows for strategic flexibility and potential inorganic growth opportunities. Additionally, the long-term potential for regulatory approvals in various therapeutic areas adds to the positive outlook. These factors, combined with a revised price target, underpin Massaro’s Buy rating for MaxCyte.
Massaro covers the Healthcare sector, focusing on stocks such as NeoGenomics, Zoetis, and Natera. According to TipRanks, Massaro has an average return of -9.3% and a 28.43% success rate on recommended stocks.
Questions or Comments about the article? Write to editor@tipranks.com